{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:40:28Z","timestamp":1729010428046},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T00:00:00Z","timestamp":1728000000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s13555-024-01277-y","type":"journal-article","created":{"date-parts":[[2024,10,4]],"date-time":"2024-10-04T11:02:59Z","timestamp":1728039779000},"page":"2889-2903","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021"],"prefix":"10.1007","volume":"14","author":[{"given":"Evelyn","family":"Meulewaeter","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anke","family":"Eylenbosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien","family":"Verhaeghe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rani","family":"Soenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,4]]},"reference":[{"issue":"2","key":"1277_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Investig Dermatol. 2013;133(2):377\u201385.","journal-title":"J Investig Dermatol"},{"issue":"19","key":"1277_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"2","key":"1277_CR3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1277_CR4","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.semarthrit.2018.01.003","volume":"48","author":"L Scotti","year":"2018","unstructured":"Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(1):28\u201334.","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"1277_CR5","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jaad.2012.08.015","volume":"68","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. 2013;68(4):654\u201362.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1277_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/2013.jamadermatol.406","volume":"149","author":"AW Armstrong","year":"2013","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol. 2013;149(1):84\u201391.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"1277_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ad.2014.10.001","volume":"106","author":"T Torres","year":"2015","unstructured":"Torres T, Puig L. Treatment goals for psoriasis: should PASI\u00a090 become the standard of care? Actas Dermosifiliogr. 2015;106(3):155\u20137.","journal-title":"Actas Dermosifiliogr"},{"issue":"5","key":"1277_CR8","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/bjd.18333","volume":"182","author":"SK Mahil","year":"2020","unstructured":"Mahil SK, Wilson N, Dand N, et al. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). Br J Dermatol. 2020;182(5):1158\u201366.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1277_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/09546634.2016.1255304","volume":"28","author":"J Lambert","year":"2017","unstructured":"Lambert J, Ghislain PD, Lambert J, Cauwe B, Van den Enden M. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). J Dermatol Treat. 2017;28(5):394\u2013400.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"1277_CR10","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1111\/jdv.15878","volume":"34","author":"M Masson Regnault","year":"2020","unstructured":"Masson Regnault M, Casta\u00f1eda-Sanabria J, Diep Tran MHT, et al. Users of biologics in clinical practice: would they be eligible for phase\u00a0III clinical studies? Cohort Study in the French Psoriasis Registry PSOBIOTEQ. J Eur Acad Dermatol Venereol. 2020;34(2):293\u2013300.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1277_CR11","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1111\/bjd.17849","volume":"181","author":"ZZN Yiu","year":"2019","unstructured":"Yiu ZZN, Mason KJ, Barker J, et al. A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. Br J Dermatol. 2019;181(6):1265\u201371.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1277_CR12","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1159\/000529398","volume":"239","author":"N Hilhorst","year":"2023","unstructured":"Hilhorst N, Deprez E, Roman E, et al. PsoPlus: an integrated practice unit for psoriasis. Dermatology. 2023;239(3):334\u201344.","journal-title":"Dermatology"},{"issue":"4","key":"1277_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.3109\/09546634.2015.1117566","volume":"27","author":"E DeCoster","year":"2016","unstructured":"DeCoster E, Alves de Medeiros A, Bostoen J, et al. A multileveled approach in psoriasis assessment and follow-up: a proposal for a tailored guide for the dermatological practice. J Dermatol Treat. 2016;27(4):298\u2013310.","journal-title":"J Dermatol Treat"},{"issue":"2","key":"1277_CR14","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377\u201381.","journal-title":"J Biomed Inform"},{"key":"1277_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"issue":"2","key":"1277_CR16","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","volume":"78","author":"B Strober","year":"2018","unstructured":"Strober B, Karki C, Mason M, et al. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry. J Am Acad Dermatol. 2018;78(2):323\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1277_CR17","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1111\/j.1365-2133.2008.09019.x","volume":"160","author":"RJ Driessen","year":"2009","unstructured":"Driessen RJ, Boezeman JB, van de Kerkhof PC, de Jong EM. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome. Br J Dermatol. 2009;160(3):670\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1277_CR18","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/bjd.13908","volume":"173","author":"IY Iskandar","year":"2015","unstructured":"Iskandar IY, Ashcroft DM, Warren RB, et al. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register. Br J Dermatol. 2015;173(2):510\u20138.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1277_CR19","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/ijd.13543","volume":"56","author":"M Kojanova","year":"2017","unstructured":"Kojanova M, Fialova J, Cetkovska P, et al. Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries. Int J Dermatol. 2017;56(4):428\u201334.","journal-title":"Int J Dermatol"},{"issue":"4","key":"1277_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40257-017-0274-0","volume":"18","author":"D H\u00e4gg","year":"2017","unstructured":"H\u00e4gg D, Sundstr\u00f6m A, Eriksson M, Schmitt-Egenolf M. Severity of psoriasis differs between men and women: a study of the clinical outcome measure Psoriasis Area And Severity Index (PASI) in 5438 Swedish Register patients. Am J Clin Dermatol. 2017;18(4):583\u201390.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1277_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.13013","volume":"171","author":"AB Kimball","year":"2014","unstructured":"Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). Br J Dermatol. 2014;171(1):137\u201347.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1277_CR22","first-page":"48","volume":"12","author":"M Augustin","year":"2014","unstructured":"Augustin M, Spehr C, Radtke MA, et al. German psoriasis registry PsoBest: objectives, methodology and baseline data. J Dtsch Dermatol Ges. 2014;12(1):48\u201357.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"5","key":"1277_CR23","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1001\/jama.2012.39","volume":"307","author":"KM Flegal","year":"2012","unstructured":"Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999\u20132010. JAMA. 2012;307(5):491\u20137.","journal-title":"JAMA"},{"key":"1277_CR24","unstructured":"Drieskens S. Gezondheidsenqu\u00eate 2018. 2018. https:\/\/www.sciensano.be\/sites\/default\/files\/nh_rapport2_his2018_nl_v3.pdf."},{"issue":"12","key":"1277_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.","journal-title":"Nutr Diabetes"},{"issue":"9","key":"1277_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1277_CR27","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1159\/000156599","volume":"217","author":"L Naldi","year":"2008","unstructured":"Naldi L, Addis A, Chimenti S, et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project. Dermatology. 2008;217(4):365\u201373.","journal-title":"Dermatology"},{"issue":"4","key":"1277_CR28","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"NJ Korman","year":"2020","unstructured":"Korman NJ. Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol. 2020;182(4):840\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"1277_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediat Inflamm. 2005;2005(5):273\u20139.","journal-title":"Mediat Inflamm"},{"key":"1277_CR30","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/819149","volume":"2015","author":"PS de Oliveira","year":"2015","unstructured":"de Oliveira PS, Cardoso PR, Lima EV, et al. IL-17A, IL-22, IL-6, and IL-21 serum levels in plaque-type psoriasis in Brazilian patients. Mediat Inflamm. 2015;2015:819149.","journal-title":"Mediat Inflamm"},{"issue":"2","key":"1277_CR31","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3109\/09546634.2014.880396","volume":"26","author":"G Girolomoni","year":"2015","unstructured":"Girolomoni G, Griffiths CE, Krueger J, et al. Early intervention in psoriasis and immune-mediated inflammatory diseases: a hypothesis paper. J Dermatol Treat. 2015;26(2):103\u201312.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"1277_CR32","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/jdv.16104","volume":"34","author":"L Grine","year":"2020","unstructured":"Grine L, de la Brassinne M, Ghislain PD, et al. A Belgian consensus on the definition of a treat-to-target outcome set in psoriasis management. J Eur Acad Dermatol Venereol. 2020;34(4):676\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1277_CR33","doi-asserted-by":"publisher","first-page":"AB37","DOI":"10.1016\/j.jaad.2023.07.153","volume":"89","author":"T Hillary","year":"2023","unstructured":"Hillary T, Ghys L, Willaert F, et al. 40351 disease severity in moderate-to-severe plaque psoriasis: results from the Belgian REDISCOVER study. J Am Acad Dermatol. 2023;89(3):AB37.","journal-title":"J Am Acad Dermatol"},{"key":"1277_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llae282","author":"LMH Arancio","year":"2024","unstructured":"Arancio LMH, D'Amico D, Dastoli S, et al. Early intervention and cumulative life course impairment in psoriasis: a review. Clin Exp Dermatol. 2024. https:\/\/doi.org\/10.1093\/ced\/llae282.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1277_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.abd.2023.08.006","volume":"99","author":"R Romiti","year":"2024","unstructured":"Romiti R, Magalh\u00e3es RF, Duarte GV. Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis. An Bras Dermatol. 2024;99(2):269\u201376.","journal-title":"An Bras Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01277-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01277-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T16:04:37Z","timestamp":1729008277000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01277-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["1277"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01277-y","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"10 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jo Lambert has received grants scientific research grants (University of Ghent account) from Janssen, AbbVie and Pfizer; paid consultancies for scientific research (University of Ghent account) from AbbVie, Almirall, Argenx, BMS, Janssen Cilag, Pfizer, Leo Pharma, Novartis and UCB; and carried out clinical trials for Janssen-Cilag, Merck Serono, Amgen, Pfizer, AbbVie, Celgene, Regeneron and Novartis. All fees were paid to the University of Ghent. Evelyn Meulewaeter changed her affiliation during completion of the manuscript to Vitaz, Moerlandstraat 1, 9100 Sint-Niklaas. The other authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Approval of this study by the Ethical Committee of Ghent University Hospital (reference number BC-09420) was obtained. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All subjects provided written informed consent to participate in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}